Yi-Wei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yi-Wei Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Hechen Rong
Department of Infectious diseases, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China
1 shared publication - Kun Wang
Department of Infectious diseases, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China
1 shared publication - Li Liang
Shanghai Clinical Research Center for Infectious Disease(TB), Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China
1 shared publication - Liping Yan
Shanghai Clinical Research Center for Infectious Disease(TB), Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China
1 shared publication - Nan Zheng
Department of Infectious diseases, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China
1 shared publication Qin-Qi Zhou
Shanghai Clinical Research Center for Infectious Disease(TB), Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
Risk factors and prognosis of Tuberculous pleural effusion in TB patients
- 22 October 2026
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
Open AccessRisk factors and prognosis of Tuberculous pleural effusion in TB patients
- Open Access
- 1 September 2022
- Published by Wolters Kluwer Health in Infectious Diseases & Immunity
- Vol. 3 (2) , 97-100
The Mechanisms of Luteolin in Treating COVID-19 Based on Bioinformatics Analysis and Molecular Docking
Luteolin is a natural flavonoid that has a variety of pharmacological activities, such as anti-inflammatory, anti-allergic, anti-bacterial, anti-viral, apoptosis inhibition, cell autophagy regulation, and anti-tumor activity. It is one of the main ingredients of an expert-recommended herbal formula for the prevention and treatment of coronavirus disease 2019 (COVID-19). This suggests that luteolin has strong pharmacological effects on the prevention and treatment of COVID-19. The aims of this study were to identify the molecular targets of luteolin and to infer the possible mechanisms by which it exerts its pharmacological effects. The GSE159787 data set was obtained from the Gene Expression Omnibus online database, and differentially expressed genes were analyzed. There were 22 upregulated differentially expressed genes enriched in the COVID-19 signaling pathway, suggesting that the upregulation of these genes may be closely related to the occurrence of COVID-19. Molecular docking results showed that luteolin had strong binding efficiency to 20 of these 22 key genes. Six of these genes (CFB, EIF2AK2, OAS1, MAPK11, OAS3, and STAT1) showed strong binding activity. Luteolin can regulate the COVID-19 signaling pathway by combining with these targets, which may have a therapeutic effect on COVID-19.
- 1 September 2022
- Published by Wolters Kluwer Health in Infectious Diseases & Immunity
- Vol. 3 (2) , 97-100
Open AccessThe Mechanisms of Luteolin in Treating COVID-19 Based on Bioinformatics Analysis and Molecular Docking
Luteolin is a natural flavonoid that has a variety of pharmacological activities, such as anti-inflammatory, anti-allergic, anti-bacterial, anti-viral, apoptosis inhibition, cell autophagy regulation, and anti-tumor activity. It is one of the main ingredients of an expert-recommended herbal formula for the prevention and treatment of coronavirus disease 2019 (COVID-19). This suggests that luteolin has strong pharmacological effects on the prevention and treatment of COVID-19. The aims of this study were to identify the molecular targets of luteolin and to infer the possible mechanisms by which it exerts its pharmacological effects. The GSE159787 data set was obtained from the Gene Expression Omnibus online database, and differentially expressed genes were analyzed. There were 22 upregulated differentially expressed genes enriched in the COVID-19 signaling pathway, suggesting that the upregulation of these genes may be closely related to the occurrence of COVID-19. Molecular docking results showed that luteolin had strong binding efficiency to 20 of these 22 key genes. Six of these genes (CFB, EIF2AK2, OAS1, MAPK11, OAS3, and STAT1) showed strong binding activity. Luteolin can regulate the COVID-19 signaling pathway by combining with these targets, which may have a therapeutic effect on COVID-19.